Menin
A scaffold protein that certain leukaemias need to keep their genes switched on; the first drug against it was approved in 2024.
Revumenib (Revuforj) is approved for KMT2A-rearranged and NPM1-mutant acute leukaemia; ziftomenib followed. Menin inhibitors are the first transcription-complex disruptors in routine haematology, and combinations with venetoclax and azacitidine are in phase 3.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · A scaffold protein that certain leukaemias need to keep their genes switched on; the first drug against it was approved in 2024.
- 1 · What it is
A scaffold protein that certain leukaemias need to keep their genes switched on; the first drug against it was approved in 2024.
- 2 · What goes wrong in cancer
Menin is a scaffold linking KMT2A fusion proteins to chromatin; inhibitors displace the complex and differentiate blasts.
- 3 · How drugs use it
2 products aim at Menin: small molecules. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Biology
Menin is a scaffold linking KMT2A fusion proteins to chromatin; inhibitors displace the complex and differentiate blasts.
- KMT2A-rearranged AML/ALL
- NPM1-mutant AML
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute myeloid leukaemia | 25-30% | NPM1 mutation | KMT2A rearrangement ~5-10% | cBioPortal (TCGA) |
| Acute lymphoblastic leukaemia | 5-10% | KMT2A rearrangement (adult); ~70% infant ALL | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Revumenib (Revuforj) is the first menin inhibitor (2024), for acute leukaemias with KMT2A rearrangements or NPM1 mutations.
Ziftomenib is the second menin inhibitor for leukaemia, approved in November 2025 as a once-daily pill for relapsed NPM1-mutated AML.
Latest papers
topQuery for this target: (TITLE:"Menin" OR ABSTRACT:"Menin" OR TITLE:"MEN1" OR ABSTRACT:"MEN1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Menin, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetEZH2
Shares Hallmark (2022): unlocking phenotypic plasticity, Cancer stem cells & phenotypic plasticity, Epigenetic reprogramming, Transcriptional machinery & addiction and the tag epigenetic.
- TargetIDH1 / IDH2
Shares Differentiation syndrome, Epigenetic reprogramming, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag epigenetic.
- CompanyKura Oncology
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Ziftomenib, Acute myeloid leukaemia.
- CompanySyndax Pharmaceuticals
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- TrialInterfant-06
Shares Menin inhibitors for infant KMT2A-rearranged ALL, KMT2A (MLL) rearrangement, Acute lymphoblastic leukaemia.
- ProductAzacitidine
Shares Menin inhibitor + venetoclax + azacitidine, Intrinsic apoptosis (BCL-2 family), Epigenetic reprogramming, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- ProductEnasidenib
Shares Differentiation syndrome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- ProductGilteritinib
Shares Eunice S. Wang, Differentiation syndrome, Acute myeloid leukaemia.